This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Tamoxifen Citrate

Read time: 1 mins
Marketing start date: 28 Apr 2024
...
 

Summary of product characteristics


Effective Time

20230928

Version

6

Spl Product Data Elements

Tamoxifen Citrate Tamoxifen Citrate TAMOXIFEN CITRATE TAMOXIFEN CARBOXYMETHYLCELLULOSE CALCIUM HYPROMELLOSES MAGNESIUM STEARATE MANNITOL POLYETHYLENE GLYCOL, UNSPECIFIED STARCH, CORN TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 826 Tamoxifen Citrate Tamoxifen Citrate TAMOXIFEN CITRATE TAMOXIFEN CARBOXYMETHYLCELLULOSE CALCIUM HYPROMELLOSES MAGNESIUM STEARATE MANNITOL POLYETHYLENE GLYCOL, UNSPECIFIED STARCH, CORN TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 827

Application Number

ANDA206694

Brand Name

Tamoxifen Citrate

Generic Name

Tamoxifen Citrate

Product Ndc

70771-1185

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1184-1 in bottle of 100 tablets Tamoxifen Citrate Tablets USP, 10 mg Rx Only 100 tablets NDC 70771-1185-1 in bottle of 100 tablets Tamoxifen Citrate Tablets USP, 20 mg Rx Only 100 tablets tamoxifen tablets tamoxifen tablets

Spl Medguide

SPL MEDGUIDE

Drug section

CDK 4/6 teaser image
CDK 4/6 teaser image
Learning Zone

CDK4/6 inhibitors in breast cancer

Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?

Learn more
199 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.